NEWS
PRESS CENTER
[Re-election or Appointment of Director subject to Shareholders' Approval / General Mandate / Explanatory Statement for Repurchase of Shares / Share Scheme] - PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED ADOPTION OF THE SHARE AWARD SCHEME; AND NOTICE OF ANNUAL GENERAL MEETING
2024-05-22
Last:[VOLUNTARY ANNOUNCEMENT] - APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE PHASE III
CLINICAL TRIAL PROTOCOL OF LAE002 (AFURESERTIB) PLUS LAE001 FOR THE TREATMENT OF PROSTATE CANCER
CLINICAL TRIAL PROTOCOL OF LAE002 (AFURESERTIB) PLUS LAE001 FOR THE TREATMENT OF PROSTATE CANCER
Next:[Notice of AGM / Closure of Books or Change of Book Closure Period] - NOTICE OF ANNUAL GENERAL MEETING
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. Privacy Policy
